Dyne Therapeutics is off to a strong start in 2024 with positive trial data from its Duchenne muscular dystrophy (DMD) program.
The company released positive initial proof-of-concept data for its two lead programs, targeting muscle diseases DM1 and DMD. The data reveals dose-dependent biomarker changes in DM1 and lower or less frequent dosing efficacy in DMD, showcasing promising early functional benefits.
In DM1, where there is currently no approved drug, the company observed positive changes related to the disease at low doses and saw early functional benefits even at the lowest dose.
For DMD, they noticed lower and less frequent dosing of a biomarker called dystrophin compared to the standard treatment, eteplirsen. Dyne plans to provide more detailed updates in the second half of 2024, including information about the best dosage and treatment schedule, as well as their plan for moving towards regulatory approval.
Dyne shares spiked on the back of the news, and the company looked to capitalize on its momentum with a $175 million financing this week.
The entirety of the shares in this proposed offering will be sold by Dyne Therapeutics, marking a strategic move to raise capital for advancing its innovative therapies in the clinical pipeline.
For DYNE-101 in DM1, the ACHIEVE trial shows positive biomarker changes, with 40% mean DMPK knockdown and -19% splicing correction at the 3.4 mg/kg Q4W IV dosage.
Analysts at Jefferies have rated the stock as a Buy with a target price of $36, representing a potential upside of around 180%.
Jefferies noted that the study suggests potential for less frequent dosing, with functional improvement observed at the lowest DYNE-101 dose.
They estimate that their treatment might become available on the market around 2028.
Shares of Dyne were up 41% on Thursday at $19.15.